Patents Examined by Matthew Coughlin
  • Packaged product of solid preparation containing 5-hydroxy-1H-imidazole-4-carboxamide or salt thereof, or hydrate thereof
    Patent number: 9481652
    Abstract: The present invention provides a packaged product of a solid preparation containing 5-hydroxy-1H-imidazole-4-carboxamide or a salt thereof, or a hydrate thereof, which comprises the solid preparation and an environment-controlling agent packaged together. The packaged product of present invention is useful as a packaged product of a solid preparation containing 5-hydroxy-1H-imidazole-4-carboxamide or a salt thereof, or a hydrate thereof, with which discoloration of the solid preparation is suppressed, and superior storage stability of the solid preparation is obtained.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: November 1, 2016
    Assignee: FUJIFILM Corporation
    Inventor: Shumma Nakano
  • Compositions and methods for the treatment of urea cycle disorders and gout
    Patent number: 9475747
    Abstract: The disclosures herein provide compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI and Formula VII or its pharmaceutical acceptable compositions and salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. The pharmaceutical compositions may be formulated for oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, nanoparticle, buccal administration or transdermal administration. Such compositions may be used to treatment of urea cycle disorders and gout or its associated complications.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: October 25, 2016
    Inventor: Mohan Murali Alapati
  • Thiadiazolidinediones as GSK-3 inhibitors
    Patent number: 9469618
    Abstract: The present invention relates to new thiadiazolidinediones of formula (I), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, particularly neurodegenerative diseases, inflammatory and autoimmune diseases and cardiovascular disorders. Additionally, there is provided a process for preparing such compounds, as well as pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: October 18, 2016
    Assignee: ASD THERAPEUTICS PARTNERS, LLC
    Inventors: Miguel Medina Padilla, Juan Manuel Domínguez Correa, Javier de Cristobal Blanco, Ana Fuertes Huerta, Jorge Sánchez-Quesada, Javier López Ogalla, Susana Herrero Santos, María Ángeles Pérez de la Cruz Moreno, Olga Martínez Montero, Beatriz Rodríguez Salguero, Francisco Palomo Nicolau
  • 2-aminothiazole derivative and anti-cancer composition comprising same as active ingredient
    Patent number: 9457015
    Abstract: The present invention relates to a novel 2-aminothiazole derivative, N-(5-(4-fluorophenyl)thiazole-2-il)-3-(furan-2-il)propane amide and to a use thereof as an anti-cancer drug. It is verified that the compound of the present invention has highly superior cancer cell-specific cytotoxic activity and in-vivo anti-cancer activity for inhibiting the growth of tumors in an animal model for cancer disease, and therefore can be developed as an anti-cancer candidate substance.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: October 4, 2016
    Assignee: Chung-Ang University Industry-Academic Cooperation Foundation
    Inventor: Seung Wook Ham
  • Intermediate for manufacture of polymerizable compound and process for manufacture thereof
    Patent number: 9447059
    Abstract: The present invention pertains to a compound represented by a formula (I) and a method for producing thereof (in the formula, Ax is an organic group having 2 to 30 carbon atoms that includes at least one aromatic ring selected from a group consisting of an aromatic hydrocarbon ring and an aromatic hetero ring, Ay is a hydrogen atom, an alkyl group having 1 to 18 carbon atoms, a cycloalkyl group, an alkenyl group having 2 to 18 carbon atoms, an organic group having 2 to 30 carbon atoms that includes at least one aromatic ring selected from a group consisting of an aromatic hydrocarbon ring and an aromatic hetero ring, or the like. Ax and Ay optionally bond to each other to form a ring, and Q is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like.).
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: September 20, 2016
    Assignee: ZEON CORPORATION
    Inventors: Kei Sakamoto, Kumi Okuyama, Yasushi Nakano
  • 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1H-pyrrol-3-yl)benzenesulfonamide as alpha 7 nAChR modulator
    Patent number: 9447037
    Abstract: Disclosed are an alpha 7 nAChR receptor modulator compound, 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1H-pyrrol-3-yljbenzenesulfonamide, its tautomeric form, its pharmaceutically acceptable salts, pharmaceutical compositions comprising the compound or a salt thereof, and a method of treating various diseases, disorders or conditions, for example, Alzheimer's disease, mild cognitive impairment, senile dementia, vascular dementia, dementia of Parkinson's disease, and attention deficit disorder.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: September 20, 2016
    Assignee: Lupin Limited
    Inventors: Neelima Sinha, Navnath Popat Karche, Ajay Ramchandra Tilekar, Venkata P. Palle, Rajender Kumar Kamboj
  • ()-2?-vinyl-abscisic acid derivatives
    Patent number: 9447015
    Abstract: The invention relates to a novel class of (S)-2?-vinyl-substituted-abscisic acid derivatives, and to methods of synthesizing and using the derivatives.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: September 20, 2016
    Assignee: Valent BioSciences Corporation
    Inventors: Gary T. Wang, Daniel F. Heiman, Gregory D. Venburg, Joseph Lustig, Marci Ann Surpin, Robert Erwin Fritts, Jr., Franklin Paul Silverman, Derek D. Woolard
  • Organic dyes, process for producing the same and use thereof
    Patent number: 9447115
    Abstract: The present invention provides an organic dye, a process for producing the same and the use thereof. The organic dye has the structure of formula (I) or formula (II). The regulation of the molecular energy levels and three-dimensional structures are achieved by ring-merging phenanthrocarbazole and an electron-rich thiophene unit as well as by selecting appropriate substituents. Thereby, when the organic dye of the present invention is applied to a dye-sensitized solar cell, the power conversion efficiency of the dye-sensitized solar cell is greatly improved. Meanwhile, the raw materials for the process according to the present invention have plenty of sources with low costs, so that a commercial production can be effected.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: September 20, 2016
    Assignee: Changchun Institute of Applied Chemistry Chinese Academy of Sciences
    Inventors: Peng Wang, Zhaoyang Yao
  • Synthesis of 3,4-Bis(4-nitro-1,2,5-oxadizaol-3-yl)-1,2,5-oxadizaole-N-oxide (DNTF) using 3-chlorocarbohydroxymoyl-4-nitro-1,2,5-oxadizaole
    Patent number: 9440936
    Abstract: A novel method for preparing 3-chlorocarbohydroxymoyl-4-nitro-1,2,5-oxadiazole by reacting 4-amino-3-chlorocarbohydroxymoyl-1,2,5-oxadiazole with H2O2 and a tungsten based catalyst and use of the prepared 3-chlorocarbohydroxymoyl-4-nitro-1,2,5-oxadiazole for synthesizing 3,4-Bis(4-nitro-1,2,5-oxadizaol-3-yl)-1,2,5-oxadiazole-N-oxide (DNTF).
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: September 13, 2016
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Reddy S. Damavarapu, Raja G. Duddu, John H. Hoare
  • N-phenethylcarboxamide derivatives
    Patent number: 9440946
    Abstract: A compound of general formula (I): A process for preparing this compound. A fungicidal composition comprising a compound of general formula (I). A method for treating plants by applying a compound of general formula (I) or a composition comprising it.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: September 13, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Darren Mansfield, Pierre-Yves Coqueron, Heiko Rieck, Philippe Desbordes, Alain Villier, Marie-Claire Grosjean-Cournoyer, Pierre Genix
  • PDE9 inhibitors with imidazo triazinone backbone
    Patent number: 9434733
    Abstract: This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: September 6, 2016
    Assignee: H. LUNDBECK A/S
    Inventors: Niels Svenstrup, Klaus Bæk Simonsen, Lars Kyhn Rasmussen, Karsten Juhl, Morten Langgård, Kate Wen, Yazhou Wang
  • 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors
    Patent number: 9422243
    Abstract: There are provided substituted 3-phenyl-isoquinolin-1(2H)-one derivatives which selectively inhibit the activity of poly(ADP-ribose) polymerase PARP-1 with respect to poly(ADP-ribose) polymerase PARP-2. The compounds of the present invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: August 23, 2016
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L. a corporation
    Inventors: Gianluca Mariano Enrico Papeo, Alessandra Cirla, Matteo D'Anello, Alessandra Scolaro, Fabio Zuccotto
  • Benzothiazole derivatives and a use thereof for the treatment of cancer
    Patent number: 9421193
    Abstract: Provided are a compound represented by Formula I, a pharmaceutically acceptable salt thereof, or a solvate thereof; and a pharmaceutical composition for cancer treatment and a pharmaceutical composition for a radiation sensitizer for cancer treatment, each pharmaceutical composition including the compound of Formula I, the pharmaceutically acceptable salt thereof, or the solvate thereof: wherein, in Formula I, —R1 is a C1-C3 alkoxy, ?O, or —OH, and —R2 is a 5- or 6-membered heteroaryl including 1 to 2 hetero atoms selected from nitrogen and oxygen, wherein a carbon of the 5- or 6-membered heteroaryl is optionally substituted with a C1-C3 alkyl a C1-C3 alkoxy, or hydroxy.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: August 23, 2016
    Assignee: Korea Institute of Radiological & Medical Sciences
    Inventors: Sung Hee Hong, In Seok Hong, Kee Ho Lee
  • Process for the recovery of betaines from electrodialysis waste stream
    Patent number: 9415346
    Abstract: The present invention discloses a process for the recovery of betaines from electrodialysis (ED) waste streams, whereby said waste streams are treated with a pressure driven membrane process.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: August 16, 2016
    Assignee: Lonza Ltd.
    Inventors: Markus Bicker, Miguel Angel Caraucán Dávila
  • Process for hydrogenating ketones in the presence of Ru(II) catalysts
    Patent number: 9416100
    Abstract: The present invention relates to a process for hydrogenating a substrate comprising a carbon-heteroatom double bond, the process comprising the step of reacting the substrate with hydrogen gas in the presence of a hydrogenation catalyst, wherein the hydrogenation catalyst is a complex of formula (I): R1-10, A and Hal are as defined in the specification. The present invention also provides processes for the preparation of the complex of formula (I) and intermediates thereof.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: August 16, 2016
    Assignee: Johnson Matthey Public Limited Company
    Inventors: Alan Dyke, Damian Mark Grainger, Jonathan Alan Medlock, Hans Guenter Nedden, Jacques Jean Marie Le Paih, Stephen James Roseblade, Andreas Seger, Vilvanathan Sivakumar, Antonio Zanotti-Gerosa
  • Intermediates for producing NEP inhibitors or prodrugs thereof
    Patent number: 9403766
    Abstract: The invention relates to a new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably carboxyl group or alkyl ester.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: August 2, 2016
    Assignee: NOVARTIS AG
    Inventors: David Hook, Bernard Riss, Daniel Kaufmann, Matthias Napp, Erhard Bappert, Philippe Polleux, Jonathan Medlock, Antonio Zanotti-Gerosa
  • Azetidine amide derivatives as orexin receptor antagonists
    Patent number: 9403813
    Abstract: The present invention relates to azetidine amide derivatives derivatives of formula (I) wherein rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 2, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Martin Bolli, Christoph Boss, Christine Brotschi, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • Processes for purifying diketopyrrolopyrrole copolymers
    Patent number: 9399698
    Abstract: Processes for purifying diketopyrrolopyrrole (DPP) copolymers are disclosed. An organic phase containing the DPP copolymer is treated with an aqueous ammonia solution and then with a palladium scavenger. The DPP copolymer is then isolated, and has a very low palladium content. The resulting DPP copolymer has high mobility.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: July 26, 2016
    Assignee: XEROX CORPORATION
    Inventors: Anthony James Wigglesworth, Yiliang Wu, Cuong Vong
  • Treprostinil derivatives and compositions and uses thereof
    Patent number: 9394227
    Abstract: The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: July 19, 2016
    Assignee: CORSAIR PHARMA, INC.
    Inventors: Xiaoming Zhang, Meenakshi S. Venkatraman, Cyrus K. Becker
  • N-heteroaryl substituted aniline derivatives as HCV-antivirals
    Patent number: 9382218
    Abstract: The present invention discloses compounds of Formula (I): wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: July 5, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Marc Plancher, Robert James Weikert